natgillin/translations-raw huggingface dataset:
• Severe hepatic impairment (see sections 4.2, 4.4 and 5.2). 
• Huda okvara jeter (glejte poglavja 4.2, 4.4 in 5.2).
• Bleeding caused by blood disorders 
• krvavitve zaradi krvnih bolezni
Patients were ineligible if there was planned use of a P2Y12 receptor antagonist, dipyridamole, cilostazol, or anticoagulant therapy during the study period; if they had a bleeding disorder or a history of an ischaemic stroke or intracranial bleeding, a central nervous system tumour or an intracranial vascular abnormality; if they had had gastrointestinal bleeding within the previous 6 months or major surgery within the previous 30 days. 
Bolniki niso bili primerni, če so imeli načrtovano uporabo antagonista receptorjev P2Y12, dipiridamola, cilostazola ali antikoagulantov med obdobjem študije; če so imeli motnjo strjevanja krvi ali anamnezo ishemične možganske kapi ali intrakranialne krvavitve, tumor osrednjega živčevja ali intrakranialno žilno nepravilnost; če so imeli gastrointestinalno krvavitev v zadnjih 6 mesecih ali večjo operacijo v zadnjih 30 dneh.
• You are bleeding now. 
• če krvavite.
Clopidogrel 75 mg once daily (% patients with event) N=9291 
Klopidogrel 75 mg enkrat na dan (% bolnikov z dogodkom) n = 9291
In PEGASUS, dyspnoea was reported in 14.2% of patients taking ticagrelor 60 mg twice daily and in 5.5% of patients taking ASA alone. 
V preskušanju PEGASUS so dispnejo zabeležili pri 14,2 % bolnikov, ki so jemali 60 mg ticagrelorja dvakrat na dan, in pri 5,5 % bolnikov, ki so jemali le ASA.
Other TIMI Major 
Druge hude po TIMI
Interference with platelet function tests to diagnose heparin induced thrombocytopenia (HIT) In the heparin induced platelet activation (HIPA) test used to diagnose HIT, anti-platelet factor 4/heparin antibodies in patient serum activate platelets of healthy donors in the presence of heparin. 
Vpliv na preiskave delovanja trombocitov za diagnosticiranje s heparinom povzročene trombocitopenije (HIT - heparin induced thrombocytopenia) Pri preiskavi s heparinom povzročene aktivacije trombocitov (HIPA - heparin induced platelet activation), ki se uporablja za diagnosticiranje HIT, protitrombocitni faktor 4/heparinska protitelesa v bolnikovem serumu aktivirajo trombocite zdravih darovalcev v prisotnosti heparina.
Brilique can be administered with or without food. 
Zdravilo Brilique se lahko jemlje s hrano ali brez nje.
The tablet can also be dispersed in water and administered via a nasogastric tube (CH8 or greater). 
Tableto je mogoče tudi raztopiti v vodi in jo dati po nazogastrični sondi (CH8 ali več).
Exploratory analyses suggest a possible association with ASA dose such that reduced efficacy was observed with ticagrelor with increasing ASA doses. 
Eksploratorne analize so pokazale možno povezavo med odmerkom ASA, tako da je bila opažena manjša učinkovitost ticagrelorja z večanjem odmerkov ASA.
• You are due to have surgery (including dental work) at any time while taking Brilique. 
• če imate predvideno operacijo (to velja tudi za zobozdravstvene posege) kadarkoli med jemanjem zdravila Brilique.
SRI = serious recurrent ischaemia; RI = recurrent ischaemia; TIA = transient ischaemic attack; ATE = arterial thrombotic event. 
RPI = resna ponovna ishemija, PI = ponovna ishemija, TIA = tranzitorna ishemična ataka, ATD = arterijski trombotični dogodek.
If a patient reports new, prolonged or worsened dyspnoea this should be investigated fully and if not tolerated, treatment with ticagrelor should be stopped. 
Primere novonastale, dolgotrajne ali poslabšane dispneje je treba povsem raziskati; če je bolnik ne prenaša, je treba zdravljenje s ticagrelorjem končati.
CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of the active metabolite and their interactions with other CYP3A substrates ranges from activation through to inhibition. 
CYP3A4 je glavni encim, odgovoren za presnovo ticagrelorja in nastanek aktivnega presnovka; njuna medsebojna delovanja z drugimi substrati CYP3A segajo od aktivacije do zavrtja.
Overall outcome of bleeding rates in the PLATO study are shown in Table 2. 
Celotne rezultate deležev krvavitev v študiji PLATO prikazuje preglednica 2.
• You have an increased risk of bleeding because of: - a recent serious injury - recent surgery (including dental work, ask your dentist about this) - you have a condition that affects blood clotting - recent bleeding from your stomach or gut (such as a stomach ulcer or colon ‘polyps') 
• če imate večje tveganje krvavitev zaradi: - nedavne resne poškodbe - nedavne operacije (vključno z zobozdravstvenimi posegi, o tem se posvetujte z zobozdravnikom) - če imate kakšno motnjo strjevanja krvi - nedavne krvavitve v želodcu ali črevesu (npr. iz razjede na želodcu ali "polipov" v debelem črevesu)
PLATO Minor: Requires medical intervention to stop or treat bleeding. 
Blage po PLATO: Zahteva medicinsko ukrepanje za ustavitev ali zdravljenje krvavitve.
The observed increased risk of TIMI Major bleeding with ticagrelor 60 mg was primarily due to a higher frequency of Other TIMI Major bleedings driven by events in the gastrointestinal SOC. 
Opaženo večje tveganje za hude krvavitve po TIMI s 60 mg ticagrelorja je bilo predvsem posledica večje pogostnosti drugih hudih krvavitev po TIMI, ki so jo povzročili dogodki v organskem sistemu "Prebavila".
The rate of discontinuations with ticagrelor 60 mg due to bleeding and dyspnoea was higher in patients >75 years (42%) than in younger patients (range: 23-31%), with a difference versus placebo higher than 10% (42% vs. 29%) in patients >75 years. 
Delež prekinitev uporabe 60 mg ticagrelorja zaradi krvavitev in dispneje je bil pri bolnikih, starejših od 75 let, večji (42 %) kot pri mlajših bolnikih (razpon: od 23 do 31 %) in razlika v primerjavi s placebom je bila pri bolnikih, starejših od 75 let, več kot 10 % (42 % v primerjavi z 29 %).
Patients in PLATO receiving ticagrelor took a variety of statins, with no concern of an association with statin safety among the 93% of the PLATO cohort taking these medicinal products. 
Bolniki, ki so v študiji PLATO dobivali ticagrelor, so jemali različne statine; pri 93 % kohorte PLATO, ki je jemala ta zdravila, ni bilo nobenih pomislekov v zvezi z varnostjo statinov.
CV death, MI (excl. silent MI) or stroke Invasive intent Medical intent CV death 
nemi MI) ali možganska kap Invazivni namen Neinvazivni namen KV smrt
Brilique contains an active substance called ticagrelor. 
Zdravilo Brilique vsebuje učinkovino, imenovano ticagrelor.
Since platelets participate in the initiation and/or evolution of thrombotic complications of atherosclerotic disease, inhibition of platelet function has been shown to reduce the risk of CV events such as death, MI or stroke. 
Ker trombociti sodelujejo pri začetku in/ali razvoju trombotičnih zapletov aterosklerotične bolezni, zavrtje njihovega delovanja dokazano zmanjša tveganje za srčno-žilne dogodke, kot so smrt, miokardni infarkt ali možganska kap.
This magnitude of increased exposure is not expected to be clinically relevant to most patients. 
Za večino bolnikov ni pričakovati, da bi bila ta stopnja povečane izpostavljenosti klinično pomembna.
• the clot can cut off the blood supply completely; this can cause a heart attack (myocardial infarction) or stroke, or 
• lahko strdek povsem prekine pretok krvi - posledica je lahko srčni infarkt (miokardni infarkt) ali možganska kap, ali
• The PLATO [PLATelet Inhibition and Patient Outcomes] study, a comparison of ticagrelor to clopidogrel, both given in combination with ASA and other standard therapy. 
• Študije PLATO [PLATelet Inhibition and Patient Outcomes], ki je primerjala ticagrelor in klopidogrel, oba v kombinaciji z ASA in drugim standardnim zdravljenjem.
Intracranial bleeding: 
Intrakranialna krvavitev:
CYP2C19 and ABCB1 genotyping of 10,285 patients in PLATO provided associations of genotype groups with PLATO outcomes. 
Na podlagi genotipizacije 10.285 bolnikov glede CYP2C19 in ABCB1 v študiji PLATO so analizirali povezanost genotipskih skupin z izidi v študiji PLATO.
The higher incidence of dyspnoea with ticagrelor is not associated with new or worsening heart or lung disease (see section 4.4). 
Večja incidenca dispneje s ticagrelorjem ni povezana z novim nastankom ali poslabšanjem bolezni srca ali pljuč (glejte poglavje 4.4).
Ticagrelor reduced the occurrence of the primary composite endpoint compared to clopidogrel in both the UA/NSTEMI and STEMI population (Table 4). 
Ticagrelor je zmanjšal pojavljanje primarnega sestavljenega opazovanega dogodka v primerjavi s klopidogrelom tako v populaciji z nestabilno angino pektoris/NSTEMI kot s STEMI (preglednica 4).
Dyspnoea is usually mild to moderate in intensity and often resolves without need for treatment discontinuation. 
Dispneja je po navadi blaga do zmerna in pogosto mine, ne da bi bilo treba zdravljenje prekiniti.
• Selective Serotonin Reuptake Inhibitors (abbreviated as SSRIs) taken as antidepressants such as paroxetine, sertraline and citalopram. 
• selektivne zaviralce prevzema serotonina (s kratico: SSRI), ki se uporabljajo kot antidepresivi, npr. paroksetin, sertralin in citalopram.
How to take Brilique Do not open the blister until it is time to take your medicine. 
Ne odpirajte pretisnega omota, dokler ni čas, da vzamete zdravilo.
P-gp substrates (including digoxin, cyclosporine) Concomitant administration of ticagrelor increased the digoxin Cmax by 75% and AUC by 28%. 
Substrati P-gp (vključno z digoksinom, ciklosporinom) Sočasna uporaba ticagrelorja je povečala Cmax digoksina za 75 % in njegovo AUC za 28 %.
Co-administration of ticagrelor and CYP3A4 substrates with narrow therapeutic indices (i.e. cisapride or ergot alkaloids) is not recommended, as ticagrelor may increase the exposure to these medicinal products. 
Sočasna uporaba ticagrelorja in substratov CYP3A4 z ozkim terapevtskim indeksom (tj. cisaprida ali alkaloidov ergot) ni priporočljiva, ker ticagrelor lahko poveča izpostavljenost tem zdravilom.
Other strong inhibitors of CYP3A4 (clarithromycin, nefazodone, ritonavir and atazanavir) would be expected to have similar effects and therefore concomitant use of strong CYP3A4 inhibitors with ticagrelor is contraindicated (see section 4.3). 
Pričakovati je mogoče, da drugi močni zaviralci CYP3A4 (klaritromicin, nefazadon, ritonavir ali atazanavir) vplivajo podobno, zato je sočasna uporaba močnih zaviralcev CYP3A4 s ticagrelorjem kontraindicirana (glejte poglavje 4.3).
Platelet transfusion did not reverse the antiplatelet effect of ticagrelor in healthy volunteers and is unlikely to be of clinical benefit in patients with bleeding. 
Transfuzija trombocitov pri zdravih prostovoljcih ni odpravila antiagregacijskega učinka ticagrelorja in ni verjetno, da bi klinično koristila bolnikom s krvavitvijo.
Dyspnoea was reported in patients treated with ticagrelor. 
Dispneja je bila opisana pri bolnikih, zdravljenih s ticagrelorjem.
• Severe pain and swelling in your joints - these are signs of gout 
• hude bolečine in oteklost sklepov - to so znaki protina
Premature discontinuation with any antiplatelet therapy, including Brilique, could result in an increased risk of cardiovascular (CV) death, MI or stroke due to the patient's underlying disease. 
Prezgodnje prenehanje uporabe kateregakoli antiagregacijskega zdravila, tudi zdravila Brilique, lahko poveča tveganje kardiovaskularne smrti, miokardnega infarkta ali možganske kapi zaradi njihove osnovne bolezni.
In female rats, ticagrelor at high dose showed an increased incidence of uterine tumours (adenocarcinomas) and an increased incidence of hepatic adenomas. 
Pri podganjih samicah je ticagrelor v velikih odmerkih spremljala večja incidenca tumorjev maternice (adenokarcinomov) in večja incidenca adenomov jeter.
Paediatric population Ticagrelor has not been evaluated in a paediatric population (see sections 4.2 and 5.1). 
Pediatrična populacija Ticagrelor v pediatrični populaciji ni ovrednoten (glejte poglavji 4.2 in 5.1).
The expected effect of excessive ticagrelor dosing is prolonged duration of bleeding risk associated with platelet inhibition. 
Pričakovani učinek čezmernega odmerjanja ticagrelorja je podaljšanje tveganja krvavitev, povezano z zavrtjem trombocitov.
There were more intracranial non-procedural bleeds with ticagrelor (n=27 bleeds in 26 patients, 0.3%) than with clopidogrel (n=14 bleeds, 0.2%), of which 11 bleeds with ticagrelor and 1 with clopidogrel were fatal. 
S ticagrelorjem je bilo več intrakranialnih krvavitev, nepovezanih s postopki (n = 27 krvavitev pri 26 bolnikih, 0,3 %) kot s klopidogrelom (n = 14 krvavitev, 0,2 %); od teh je bilo smrtnih 11 krvavitev s ticagrelorjem in 1 s klopidogrelom.
Hyperuricaemia may occur during treatment with ticagrelor (see section 4.8). 
Med zdravljenjem s ticagrelorjem se lahko pojavi hiperurikemija (glejte poglavje 4.8).
Ticagrelor should be used with caution in patients with history of asthma and/or COPD. 
Ticagrelor je treba previdno uporabljati pri bolnikih z astmo in/ali KOPB.
Ingestion of a high-fat meal resulted in a 21% increase in ticagrelor AUC and 22% decrease in the active metabolite Cmax but had no effect on ticagrelor Cmax or the AUC of the active metabolite. 
Zaužitje zelo mastnega obroka je povzročilo 21 % povečanje ticagrelorjeve AUC in 22 % zmanjšanje Cmax aktivnega presnovka, ni pa vplivalo na Cmax ticagrelorja ali AUC aktivnega presnovka.
Discontinuation of treatment due to non-procedural bleeding was more common for ticagrelor (2.9%) than for clopidogrel (1.2%; p<0.001). 
Prekinitve zdravljenja zaradi krvavitev, nepovezanih s postopki, so bile s ticagrelorjem pogostejše (2,9 %) kot s klopidogrelom (1,2 %, p < 0,001).
Other CYP3A inducers (e.g. phenytoin, carbamazepine and phenobarbital) would be expected to decrease the exposure to ticagrelor as well. 
Pričakovati je, da drugi induktorji CYP3A (npr. fenitoin, karbamazepin in fenobarbital) prav tako zmanjšajo izpostavljenost ticagrelorju.
If you stop taking Brilique 
Če ste prenehali jemati zdravilo Brilique
Pharmacokinetic studies performed with radiolabelled ticagrelor have shown that the parent compound and its metabolites are excreted in the milk of rats (see section 4.6). 
Farmakokinetične študije z radioaktivno označenim ticagrelorjem so pokazale, da se matična spojina in njeni presnovki izločajo v mleku podgan (glejte poglavje 4.6).
• Signs of a blood clotting problem called Thrombotic Thrombocytopenic Purpura (TTP) such as: - fever and purplish spots (called purpura) on the skin or in the mouth, with or without yellowing of the skin or eyes (jaundice), unexplained extreme tiredness or confusion 
• Znaki motnje v strjevanju krvi, imenovane trombotična trombocitopenična purpura (TTP), na primer: - zvišana telesna temperatura in škrlatne pike (imenovane purpura) na koži ali v ustih, s porumenelostjo kože ali oči (zlatenica) ali brez takšne porumenelosti, nepojasnjeno hudo utrujenostjo ali zmedenostjo
Based on a relationship observed in PLATO between maintenance ASA dose and relative efficacy of ticagrelor compared to clopidogrel, co-administration of ticagrelor and high maintenance dose ASA (>300 mg) is not recommended (see section 5.1). 
Glede na razmerje med vzdrževalnim odmerkom ASA in relativno učinkovitostjo ticagrelorja v primerjavi s klopidogrelom, ugotovljeno v študiji PLATO, sočasna uporaba ticagrelorja in visokega vzdrževalnega odmerka ASA (> 300 mg) ni priporočljiva (glejte poglavje 5.1).
Figure 1 - Analysis of primary clinical composite endpoint of CV death, MI and stroke (PLATO) 
Slika 1 - Analiza primarnega sestavljenega kliničnega opazovanega dogodka KV smrti, MI in možganske kapi (PLATO)
Each of the components contributed to the reduction in the primary composite endpoint (CV death 17% RRR, MI 16% RRR and stroke 25% RRR). 
Vsak od elementov je pripomogel k zmanjšanju primarnega sestavljenega opazovanega dogodka (kardiovaskularna smrt 17 % RRR, miokardni infarkt 16 % RRR in možganska kap 25 % RRR).
Ticagrelor orodispersible tablets, dispersed in saliva and swallowed without water or suspended in water and administered through a nasogastric tube into the stomach, were bioequivalent to film-coated whole tablets (AUC and Cmax within 80-125% for ticagrelor and the active metabolite). 
Orodisperzibilne tablete ticagrelorja, raztopljene v slini in zaužite brez vode ali raztopljene v vodi in dane po nazogastrični sondi v želodec, so bioekvivalentne filmsko obloženim celim tabletam (AUC in Cmax ticagrelorja in aktivnega presnovka sta znotraj 80-125 %).
Co-administration of ticagrelor with heparin, enoxaparin or desmopressin had no effect on activated partial thromboplastin time (aPTT), activated coagulation time (ACT) or factor Xa assays. 
Sočasna uporaba ticagrelorja s heparinom, enoksaparinom ali dezmopresinom ni vplivala na aktivirani parcialni tromboplastinski čas (aPTT), aktivirani koagulacijski čas (ACT) ali teste faktorja Xa.
Bleeding findings in PLATO 
Izsledki o krvavitvah v študiji PLATO
• Simvastatin - Co-administration of ticagrelor with simvastatin increased simvastatin Cmax by 81% and AUC by 56% and increased simvastatin acid Cmax by 64% and AUC by 52% with some individual increases equal to 2- to 3-fold. 
• Simvastatin - Sočasna uporaba ticagrelorja in simvastatina je povečala Cmax simvastatina za 81 % in njegovo AUC za 56 %; Cmax simvastatinske kisline je povečala za 64 % in njeno AUC za 52 %, pri nekaterih posameznikih pa so bila povečanja 2- do 3-kratna.
• quinidine and diltiazem (used to treat abnormal heart rhythms) 
• kinidin in diltiazem (uporabljata se za zdravljenje motenj srčnega ritma)
Creatinine elevations 
Zvišanje kreatinina
If you take more Brilique than you should, talk to a doctor or go to hospital straight away. 
Če ste vzeli večji odmerek zdravila Brilique, kot bi smeli Če vzamete več zdravila Brilique, kot bi smeli, se morate takoj posvetovati z zdravnikom ali iti v bolnišnico.
Co-administration of ticagrelor with potent CYP3A inducers may decrease exposure and efficacy of ticagrelor, therefore, their concomitant use with ticagrelor is discouraged. 
Sočasna uporaba ticagrelorja z močnimi induktorji CYP3A lahko zmanjša izpostavljenost ticagrelorju in njegovo učinkovitost, zato njihova sočasna uporaba s ticagrelorjem ni priporočljiva.
The major metabolite of ticagrelor is AR-C124910XX, which is also active as assessed by in vitro binding to the platelet P2Y12 ADP-receptor. 
Glavni presnovek ticagrelorja je AR-C124910XX, ki je tudi aktiven, kot je bilo ugotovljeno z vezavo na trombocitni ADP-receptor P2Y12 in vitro.
Therefore, due to the limited clinical experience, ticagrelor should be used with caution in these patients (see section 5.1). 
Zato je treba ticagrelor zaradi omejenih kliničnih izkušenj pri takšnih bolnikih uporabljati previdno (glejte poglavje 5.1).
It is characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal dysfunction or fever. 
Značilni zanjo sta trombocitopenija in mikroangiopatična hemolitična anemija, ki ju spremljajo nevrološke spremembe, moteno delovanje ledvic ali zvišana telesna temperatura.
10 x 1 orodispersible tablets 56 x 1 orodispersible tablets 60 x 1 orodispersible tablets 
10 x 1 orodisperzibilna tableta 56 x 1 orodisperzibilna tableta 60 x 1 orodisperzibilna tableta
Table 2 - Analysis of overall bleeding events, Kaplan-Meier estimates at 12 months (PLATO) 
- Analiza vseh dogodkov, povezanih s krvavitvami, Kaplan-Meierjeve ocene po 12 mesecih (PLATO)
A similar increase in exposure was observed when ticagrelor was administered immediately prior to dialysis (49% and 61%, respectively) showing that ticagrelor is not dialysable. 
Podobno povečanje izpostavljenosti so opažali v primeru uporabe ticagrelorja tik pred dializo (AUC 49 % in Cmax 61 %); to kaže, da se ticagrelor ne dializira.
• Internal bleeding, this may cause dizziness or light-headedness 
• notranja krvavitev, povzroči lahko omotico ali vrtoglavico
Caution is advised in patients with history of hyperuricaemia or gouty arthritis. 
Previdnost je potrebna pri bolnikih z anamnezo hiperurikemije ali uričnega artritisa.
Gastrointestinal haemorrhage g, 
Bolezni prebavil gastrointestinalna krvavitev g, driska,
Co-administration of ticagrelor with doses of simvastatin exceeding 40 mg daily could cause adverse reactions of simvastatin and should be weighed against potential benefits. 
Sočasna uporaba ticagrelorja in več kot 40 mg simvastatina na dan lahko povzroči neželene učinke simvastatina in jo je treba pretehtati glede na možne koristi.
• digoxin (used to treat heart failure) 
• digoksin (uporablja se za zdravljenje srčnega popuščanja)
Ticagrelor has not been studied in patients with severe hepatic impairment and its use in these patients is therefore contraindicated (see section 4.3). 
Ticagrelor ni raziskan pri bolnikih s hudo okvaro jeter in njegova uporaba pri teh bolnikih je zato kontraindicirana (glejte poglavje 4.3).
Hazard ratio and p-values are calculated separately for ticagrelor vs. ASA therapy alone from Cox proportional hazards model with treatment group as the only explanatory variable. 
Razmerje ogroženosti in vrednosti p so izračunani ločeno za ticagrelor v primerjavi z zdravljenjem z ASA samo iz Coxovega modela sorazmernih ogroženosti s terapevtsko skupino kot edino eksplanatorno spremenljivko.
Warnings and precautions Talk to your doctor or pharmacist before taking Brilique if: 
Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila Brilique, se posvetujte z zdravnikom ali farmacevtom:
No data are available on concomitant use of ticagrelor with other active substances that also are potent P-gp inhibitors and moderate CYP3A4 inhibitors (e.g. verapamil, quinidine) that also may increase ticagrelor exposure. 
Ni podatkov o sočasni uporabi ticagrelorja z drugimi učinkovinami, ki so prav tako močni zaviralci P-gp in zmerni zaviralci CYP3A4 (npr. verapamil, kinidin) in lahko prav tako povečajo izpostavljenost ticagrelorju.
• Vaginal bleeding that is heavier, or happens at different times, than your normal period 
• krvavitev iz nožnice, ki je močnejša ali se pojavi ob drugem času kot normalna menstruacijska krvavitev
• Bleeding into the brain or inside the skull is an uncommon side effect, and may cause signs of a stroke such as: - sudden numbness or weakness of your arm, leg or face, especially if only on one side of the body - sudden confusion, difficulty speaking or understanding others - sudden difficulty in walking or loss of balance or co-ordination - suddenly feeling dizzy or sudden severe headache with no known cause 
• Krvavitev v možgane ali v lobanjo je občasen neželeni učinek in lahko povzroči znake možganske kapi, na primer: - nenadno omrtvelost ali šibkost roke, noge ali obraza, še zlasti, če se pojavi le na eni strani telesa - nenadno zmedenost, težave z govorjenjem ali razumevanjem tistega, kar vam povedo drugi - nenadne težave s hojo ali izgubo ravnotežja ali koordinacije gibov - nenadno omotico ali nenaden hud glavobol brez znanega vzroka
Dose adjustment is not recommended, but ticagrelor should be used with caution (see sections 4.4 and 5.2). 
Prilagoditev odmerka ni potrebna, a je ticagrelor treba uporabljati previdno (glejte poglavji 4.4 in 5.2).
Ticagrelor has been documented to augment the following adenosine-induced effects in healthy subjects and in patients with ACS: vasodilation (measured by coronary blood flow increases in healthy volunteers and ACS patients; headache), inhibition of platelet function (in human whole blood in vitro) and dyspnoea. 
Ugotovljeno je, da ticagrelor pri zdravih osebah in bolnikih z akutnim koronarnim sindromom poveča naslednje učinke, izzvane z adenozinom: vazodilatacijo (merjeno s povečanjem koronarnega pretoka krvi pri zdravih prostovoljcih in bolnikih z akutnim koronarnim sindromom; glavobol), zavrtje delovanja trombocitov (v polni človeški krvi in vitro) in dispnejo.